Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta Inc (Nasdaq: AZTA) is a global leader in life sciences solutions, providing essential tools for drug development, clinical research, and genomic discovery. This page aggregates official press releases and verified news about the company’s advancements in cold-chain sample management, automated storage systems, and multiomics services.
Investors and researchers will find timely updates on Azenta’s operational milestones, including earnings reports, strategic partnerships, product innovations, and industry recognition. The curated content addresses key areas such as sample integrity technologies, genomic data accuracy, and global service expansions.
Key updates include developments from Azenta’s core segments: Life Sciences Products (automated storage solutions, lab consumables) and Life Sciences Services (genomic sequencing, multiomics analytics). Content is organized to help stakeholders track progress in critical research areas like precision medicine and biotherapeutic development.
Bookmark this page for streamlined access to Azenta’s latest announcements, or check regularly for insights into how the company continues to shape the future of life sciences infrastructure and biomedical innovation.
Azenta (Nasdaq: AZTA) has been chosen by the Crohn's & Colitis Foundation for sample management services for two key research initiatives: CAPTURE IBD and IBD SIRQC. These studies focus on pediatric and surgical care for Crohn's disease and ulcerative colitis. Azenta will handle sample processing, analysis, logistics, and storage. These efforts are part of the Foundation's IBD Plexus® platform, which aims to revolutionize research with well-phenotyped data and biosamples. CAPTURE IBD is a longitudinal study enrolling thousands of pediatric patients across 12 U.S. sites. IBD SIRQC targets 5,000 patients at 9 sites, focusing on surgical outcomes. Azenta's role is anticipated to advance understanding and treatment of these diseases.
Azenta (Nasdaq: AZTA) announced its participation in the Jefferies Global Healthcare Conference in New York on June 5, 2024. The company's presentation will start at 11:00 am ET. A live webcast and a replay will be accessible on Azenta's investor relations website. This event is significant for sharing strategic updates and potential investor engagement.
Azenta has inaugurated a new Genomics Laboratory in Oxford, UK, enhancing its global GENEWIZ Multiomics & Synthesis Solutions. This facility provides UK researchers with advanced NGS platforms and local scientific expertise. The lab aims to expedite high-quality data delivery, fostering progress in critical research areas like diabetes, infectious diseases, and Alzheimer's. The lab features state-of-the-art technology from Illumina, PacBio, Oxford Nanopore, and more. It offers a comprehensive suite of services including library preparation, sequencing, and bioinformatics, supported by Ph.D.-level managers. The opening event on April 25, 2024, included a ribbon-cutting ceremony and lab tour.
Azenta, Inc. (Nasdaq: AZTA) announced a CEO succession plan with CEO Dr. Stephen Schwartz retiring after over 14 years of service. The Board is actively searching for a successor with the help of a leading executive search firm. Dr. Schwartz expressed pride in Azenta's transformation into a leading life sciences business and supports a smooth transition to the new CEO. Azenta also reported its earnings results for the second quarter of fiscal 2024.
Azenta, Inc. (Nasdaq: AZTA) reported financial results for Q2 fiscal 2024 with revenue of $159 million, up 7% YoY. Positive free cash flow for the fourth consecutive quarter. Strong organic revenue growth in Sample Management Solutions and B Medical Systems. Operating loss of $147 million, with operating margin at (92.3%). Non-GAAP diluted EPS improved to $0.05. Cash balance of $975 million. Share repurchase program ongoing. Lowered revenue guidance for FY2024 but raised earnings guidance.
Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2024 earnings on May 8, 2024, after market close. The Company will hold a conference call and webcast to discuss financial results the same day at 4:30 p.m. Eastern Time. Analysts, investors, and media can access the live webcast on the Azenta website.
FAQ
What is the current stock price of Azenta (AZTA)?
What is the market cap of Azenta (AZTA)?
